Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry; iStent Supra suprachoroidal micro-bypass stent, which is designed to reduce intraocular pressure by accessing the suprachoroidal space in the eye; and iDose, a targeted injectable drug delivery implant that is designed to be pre-loaded into a small gauge needle and injected into the eye through a self-sealing corneal needle penetration. Its product pipeline also consists of iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure; and iStent Infinite trabecular micro-bypass system, which is used as a standalone procedure in patients with refractory glaucoma. The company markets its products through direct sales force in the United States and internationally, as well as through distribution partners in Europe, the Asia Pacific, Latin America, and internationally. Glaukos Corporation has a collaboration agreement with D. Western Therapeutics Institute for the development of novel intraocular products for the treatment of glaucoma. The company was founded in 1998 and is headquartered in San Clemente, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone949-367-9600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$159.25 million
Profitability
Miscellaneous
Employees387
OptionableOptionable
Glaukos (NYSE:GKOS) Frequently Asked Questions
What is Glaukos' stock symbol?
Glaukos trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS."
How were Glaukos' earnings last quarter?
Glaukos Corp (NYSE:GKOS) released its quarterly earnings data on Thursday, August, 2nd. The medical instruments supplier reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.03. The medical instruments supplier had revenue of $43.16 million for the quarter, compared to analyst estimates of $40.51 million. Glaukos had a negative return on equity of 9.26% and a negative net margin of 8.13%. The business's revenue was up 4.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.10) earnings per share. View Glaukos' Earnings History.
When is Glaukos' next earnings date?
How can I listen to Glaukos' earnings call?
Glaukos will be holding an earnings conference call on Wednesday, February 27th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8332318262.
What price target have analysts set for GKOS?
10 Wall Street analysts have issued 1 year price objectives for Glaukos' stock. Their forecasts range from $35.00 to $75.00. On average, they expect Glaukos' stock price to reach $59.7778 in the next year. This suggests that the stock has a possible downside of 13.7%. View Analyst Price Targets for Glaukos.
What is the consensus analysts' recommendation for Glaukos?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Glaukos.
Has Glaukos been receiving favorable news coverage?
Media coverage about GKOS stock has been trending somewhat positive recently, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Glaukos earned a news sentiment score of 1.4 on InfoTrie's scale. They also gave news headlines about the medical instruments supplier a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.
Who are some of Glaukos' key competitors?
Some companies that are related to Glaukos include Hill-Rom (HRC), Penumbra (PEN), ICU Medical (ICUI), Insulet (PODD), Novocure (NVCR), Globus Medical (GMED), Haemonetics (HAE), Integra Lifesciences (IART), Cantel Medical (CMD), Merit Medical Systems (MMSI), NuVasive (NUVA), Tandem Diabetes Care (TNDM), Irhythm Technologies (IRTC), Mazor Robotics (MZOR) and Nevro (NVRO).
Who are Glaukos' key executives?
Glaukos' management team includes the folowing people:
- Mr. Thomas William Burns, CEO, Pres & Director (Age 58)
- Mr. Joseph E. Gilliam, CFO & Sr. VP of Corp. Devel. (Age 43)
- Mr. Chris M. Calcaterra, COO & Chief Commercial Officer (Age 59)
- Mr. Richard L. Harrison, Advisor (Age 62)
- Dr. Mory Gharib Ph.D., Co-Founder
When did Glaukos IPO?
(GKOS) raised $76 million in an IPO on Thursday, June 25th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs acted as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.
Who are Glaukos' major shareholders?
Glaukos' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.35%), Lord Abbett & CO. LLC (6.03%), Baillie Gifford & Co. (4.94%), New York State Common Retirement Fund (1.46%), Northern Trust Corp (1.35%) and Jennison Associates LLC (1.33%). Company insiders that own Glaukos stock include Chris M Calcaterra, Gilbert H Kliman, Jonathan Silverstein, Joseph E Gilliam, Orbimed Advisors Llc, Thomas William Burns and William J Phd Link. View Institutional Ownership Trends for Glaukos.
Which major investors are selling Glaukos stock?
GKOS stock was sold by a variety of institutional investors in the last quarter, including Amundi Pioneer Asset Management Inc., D. E. Shaw & Co. Inc., Granite Investment Partners LLC, Rhenman & Partners Asset Management AB, Bank of America Corp DE, Bank of New York Mellon Corp, Citigroup Inc. and Taylor Frigon Capital Management LLC. Company insiders that have sold Glaukos company stock in the last year include Chris M Calcaterra, Gilbert H Kliman, Jonathan Silverstein, Joseph E Gilliam, Orbimed Advisors Llc, Thomas William Burns and William J Phd Link. View Insider Buying and Selling for Glaukos.
Which major investors are buying Glaukos stock?
GKOS stock was acquired by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Victory Capital Management Inc., New York State Common Retirement Fund, Lord Abbett & CO. LLC, BlackRock Inc., SG Americas Securities LLC, Geode Capital Management LLC and California Public Employees Retirement System. View Insider Buying and Selling for Glaukos.
How do I buy shares of Glaukos?
Shares of GKOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Glaukos' stock price today?
One share of GKOS stock can currently be purchased for approximately $69.25.
How big of a company is Glaukos?
Glaukos has a market capitalization of $2.42 billion and generates $159.25 million in revenue each year. Glaukos employs 387 workers across the globe.
What is Glaukos' official website?
How can I contact Glaukos?
Glaukos' mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. The medical instruments supplier can be reached via phone at 949-367-9600 or via email at [email protected]
MarketBeat Community Rating for Glaukos (NYSE GKOS)
MarketBeat's community ratings are surveys of what our community members think about Glaukos and other stocks. Vote "Outperform" if you believe GKOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GKOS will underperform the S&P 500 over the long term. You may vote once every thirty days.
